GlassScriptPhysician profile
Elliott Eisenbud
NPI 1548288723
$1,914.94
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,310 · 2020: $126 · 2021: $165 · 2022: $205 · 2023: $37.54 · 2024: $72.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $109.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $1,026.33 | 2019 | |
| Novo Nordisk INC | $224.66 | 2019-2022 | |
| Medtronic Vascular, INC. | $132.26 | 2019 | |
| Abbott Laboratories | $84.19 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $78.87 | 2020 | |
| Amgen INC. | $76.90 | 2019-2024 | Tepezza |
| Insulet Corporation | $70.36 | 2020-2024 | Omnipod |
| Merck Sharp & Dohme LLC | $61.58 | 2022 | |
| Medtronic, INC. | $60.47 | 2022 | |
| Sanofi-Aventis U.S. LLC | $35.63 | 2019-2024 | |
| Mannkind Corporation | $33.84 | 2020 | |
| Medtronic Minimed, INC. | $15.19 | 2019 | |
| Currax Pharmaceuticals LLC | $14.66 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliott Eisenbud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.